Item 5.07. Submission of Matters to a Vote of Security Holders.
On January 13, 2023, Ayala Pharmaceuticals, Inc. (the "Company") held a Special
Meeting of Stockholders (the "Meeting"). A total of 9,408,088 shares of the
Company's common stock, $0.01 par value per share (the "Common Stock"), were
present in person or represented by proxy at the Meeting, representing
approximately 63.47% percent of the Company's outstanding Common Stock as of the
December 7, 2022 record date. The following are the voting results for the
proposals considered and voted upon at the Meeting, each of which were described
in the Company's Definitive Proxy Statement filed with the Securities and
Exchange Commission on December 12, 2022.
Item 1 - Adoption of the Agreement and Plan of Merger (the "Merger Agreement"),
dated October 18, 2022, by and among the Company, Advaxis, Inc. ("Advaxis") and
Doe Merger Sub, Inc. ("Merger Sub"), pursuant to which, among other things,
Merger Sub will merge with and into the Company, with the Company surviving as a
wholly owned subsidiary of Advaxis.
Votes FOR Votes AGAINST Votes ABSTAINED
9,382,563 24,310 1,215
Item 2 - Approval of the adjournment of the Meeting from time to time, if
necessary or appropriate, to solicit additional affirmative votes in favor of
the Merger Agreement if there are insufficient votes at the time of such
adjournment to approve the Merger Agreement.
Votes FOR Votes AGAINST Votes ABSTAINED
9,358,455 37,698 11,935
Based on the foregoing votes, Item 1 and Item 2 were approved.
© Edgar Online, source Glimpses
ADVAXIS, INC. 
